A Study of CM310 in Subjects With Moderate to Severe Asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 24-week randomized treatment period, and a 8-week safety follow-up period.
Epistemonikos ID: 04762529275f7493fbc25c2f65b463999caa3f87
First added on: May 09, 2024